Víctor Albarrán-Artahona

MD. Medical oncologist.
Head of Unit at Hospital Vithas Barcelona
PhD student Universitat de Barcelona.

[NEJM @NEJM]

Amivantamab, an antibody against MET and EGFR, plus lazertinib, an EGFR tyrosine kinase inhibitor, induced a response in 86% of previously untreated patients and led to a median progression-free survival of nearly 2 years. Full MARIPOSA trial results: https://t.co/QHsu24YpnN

[Víctor Albarrán-Artahona @vmalbarran]

#Oncologicdiseases are nowadays 1st cause of mortality in #Spain according to #INE statistics‼️

The shift is now a reality and our health system it’s not ready yet.

⚠️ How are we going to assume this? We need:
Better screening 🩻
Better drugs 💊
More approvals 💶

[Víctor Albarrán-Artahona @vmalbarran]

🚨 Sub-study from #MARIPOSA trial 🦋:

Amivantamab+Lazertinib effectively overcomes high risk feat. Vs Osi:

✅ TP53m+
✅ #ctDNA+
✅ Liver mets at baseline
✅ No ctDNA clear. after 3m

A super selection of pts seems feasible in 1st line #EGFR+ #NSCLC, but what about Osi+CT?

[Víctor Albarrán-Artahona @vmalbarran]

🔥 Just published hot content by @NEJM

🦋 #MARIPOSA trial: Amivantamab + Lazertinib vs Osimertinib in 1st line #EGFR+ Advanced Non-Small Cell #LungCancer.

⬆️mPFS 23.7 vs 16.6 m (HR: 0.7)

Are we really ready to assume also the increased toxicity?

[Marta Garcia de Herreros @MartaGdeH]

👉🏼 Check out our poster 496;
High expression of androgen receptor-gene signature correlates with better prognosis in #mHSPC ✅, while #ARV7 is associated with adverse outcomes❌
@begona_mellado #ASCO24

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Two anti-Trop2 ADCs buried together. #ASCO24 #LCSM

[Gonzalo Recondo @GRecondoMD]

Collecting data on patients lifestyle, environmental and family history of cancer can trigger measures to avoid continue carcinogen exposure for patients, their families, co-workers and general populations by @LauraMezquitaMD #ASCO24

[Jordi Remon @JordiRemon]

ICARUS-Lung Datopotomab deruxtecan in heavily pretreatred pts with NSCLC: RR 28% PFS 3.6 OS 11.9. Single arm!. Biomarker:Trop2 + >100
Exploring mec of resistance may elucidate if sequential ADCs are feasible
Are resistance mec indeprndent of tumor. Type? #ASCO24 @dplanchard

[Jordi Remon @JordiRemon]

EVOKE-01 sacituzumab govitecan vs Docet in 2L is ⛔️for OS.« Traffic light »🚦of ADCs in NSCLC is red. New biomarkers as targets for ADCs (current are prognostic), better safety of ADCs and explore mec of resistance, combos? may help to set up ADC as relevant txt in NSCLC #ASCO24

[Benjamin Besse @BenjaminBesseMD]

Lorlatinib PFS is impressive with an HR 0.19 over crizotinib.
But why after 5 yrs FU can’t we see the OS curves and the cross over rate? Even if the number of events is not reached, that would help us to select our first line treatment.
@ALKPositiveinc #ASCO24

[Benjamin Besse @BenjaminBesseMD]

LIFETIME osimertinib after a treatment with curative intent?
In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts.
Were pts in LAURA properly staged by petscan/brain RMI?
Why not using MRD to select patient?
Strong concerns when OS is not positive. #ASCO24

[Giannis Mountzios @g_mountzios]

#ELCC24 @M_Tagliamento excellent discussion on cancer vaccines in #NSCLC

➡️Cell-based vaccines ➖
➡️ Peptide vaccines:Atalante-1 in 2L pos for pts who responded to 1L IO
➡️DNA/RNA vaccines ongoing
➡️Oncogenic driver vaccines KRAS
➡️ Neoantigen selection!
#ESMOAmbassadors #some

[Gonzalo Recondo @GRecondoMD]

Global representation and research is key to unravel the role of carcinogens and lung cancer molecular subtypes. Thank you @jlaguna_ @MiguelG_pds & @LauraMezquitaMD for leading this review & all co-authors for this collaborative endeavor.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Dr. @MARIANOPROVENCI presents 3y results from CheckMate 816 by tumor PD-L1 expression. In PDL1+, pCR 32.6%, EFS HR 0.46, OS HR 0.37, 3y OS rate 85% vs 66%. Similar when looking at stage II-IIIA. Fantastic.

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

💊 Now we have efficacy data on PAN-KRAS inhibitor

RMC-6236 is a First-in-Class, RAS-MULTI (ON) Inhibitor

💥 ORR 38%, including 1 CR (n=40) for non-KRASG12C NSCLC

Just wow! @KRASKickers

#LCSM #ESMO23

[Marta Garcia de Herreros @MartaGdeH]

Thrilled to share our work on PTEN expression in mHSPC:
⛔️ Shorter PFS and OS for pts with low PTEN expression treated with ADT +/- Docetaxel
➡️ No benefit with Docetaxel
📌 Check out the RNA-seq and functional analysis
#ESMO23 @begona_mellado @OscarReigMD

[Tom Powles @tompowles1]

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

[Noemi Reguart @NReguart]

Amivantamab and chemotherapy in PAPILLON hits, and stablish a NEW SoC in patients with EGFRm exon 20 insertions, 60% reduccion in the risk of progressio. (PFS 11.4 vs 6.7 mo, HR 0.395, p<0.0001). Interym analisis inmature but preliminary OS HR 0.675. #ESMO2023

[Giannis Mountzios @g_mountzios]

Practice changing study in #ESMO23 just out in @NEJM
Chemotherapy in NSCLC with EGFR Exon 20 Insertions #Exon20ins
Great news for this rare group of patients with high unmet medical need
⁦@OncoAlert⁩ ⁦@OncBrothers⁩ ⁦⁦@Exon20Group⁩ https://t.co/vv7IHQK9QR

[Julien Mazieres @JulienMazieres]

Another big hit #ESMO23 Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT. Impressive curves and HR 0.24. Immediate Practice-changing trial. @OncoAlert @bensolomon1